Results 121 to 130 of about 96,286 (217)

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial. [PDF]

open access: yesBreast Cancer Res Treat
Hörner M   +51 more
europepmc   +1 more source

New Lives [PDF]

open access: yes, 1983
Klippel, Friederike
core  

[Implementation research-effective implementation of evidence-based interventions into practice]. [PDF]

open access: yesBundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
El Bcheraoui C, Hanefeld J, Schaade L.
europepmc   +1 more source

Conjunctival melanoma with pronounced central corneal invasion: One-year relapse free follow-up. [PDF]

open access: yesAm J Ophthalmol Case Rep
Englisch CN   +4 more
europepmc   +1 more source

Imaginative Discussions [PDF]

open access: yes, 1984
Klippel, Friederike
core  

Dipeptidic Phosphonates: Potent Inhibitors of Pseudomonas aeruginosa Elastase B Showing Efficacy in a Murine Keratitis Model. [PDF]

open access: yesAdv Sci (Weinh)
Kiefer AF   +22 more
europepmc   +1 more source

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry. [PDF]

open access: yesNPJ Breast Cancer
Hörner M   +52 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy